Thomas Danne (T Danne, Markus Laimer)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 36

Top Topics

Body Mass Index

Glycemic Control

Clinical Practice

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

Pediatric diabetes

Diabetes technology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin, Tadej Battelino, Thomas Danne, Mark L Evans, Jesper Johannesen, Simranjeet Kaur, Olli H Laitinen, Lut Overbergh, Flemming Pociot, John A Todd, Bart Van der Schueren, Linda S Wicker, Mark Peakman, Chantal Mathieu, null null
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia 67 (6) (2024)
Maria Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin, Tadej Battelino, Thomas Danne, Mark L Evans, Jesper Johannesen, Simranjeet Kaur, Olli H Laitinen, Lut Overbergh, Flemming Pociot, John A Todd, Bart Van der Schueren, Linda S Wicker, Mark Peakman, Chantal Mathieu, null null
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia (2024)
Maria Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin, Tadej Battelino, Thomas Danne, Mark L Evans, Jesper Johannesen, Simranjeet Kaur, Olli H Laitinen, Lut Overbergh, Flemming Pociot, John A Todd, Bart Van der Schueren, Linda S Wicker, Mark Peakman, Chantal Mathieu, null null
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia 67 (6) (2024)
Maria Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin, Tadej Battelino, Thomas Danne, Mark L Evans, Jesper Johannesen, Simranjeet Kaur, Olli H Laitinen, Lut Overbergh, Flemming Pociot, John A Todd, Bart Van der Schueren, Linda S Wicker, Mark Peakman, Chantal Mathieu, null null
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia 67 (6) (2024)
Maria Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin, Tadej Battelino, Thomas Danne, Mark L Evans, Jesper Johannesen, Simranjeet Kaur, Olli H Laitinen, Lut Overbergh, Flemming Pociot, John A Todd, Bart Van der Schueren, Linda S Wicker, Mark Peakman, Chantal Mathieu, null null
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia 67 (6) (2024)
Ronnie Aronson, Torben Biester, Jennifer Leohr, Robyn K Pollom, Helle Linnebjerg, Elizabeth Smith LaBell, Qianyi Zhang, David E Coutant, Thomas Danne
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents, and adults with type 1 diabetes mellitus. Diabetes, obesity & metabolism (2023)
Simon R Heller, Tadej Battelino, Timothy S Bailey, Thomas R Pieber, Ulrike Hoevelmann, Leona Plum-Mörschel, Anita E Melgaard, Ronnie Aronson, Linda A DiMeglio, Thue Johansen, Thomas Danne
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Simon R Heller, Tadej Battelino, Timothy S Bailey, Thomas R Pieber, Ulrike Hoevelmann, Leona Plum-Mörschel, Anita E Melgaard, Ronnie Aronson, Linda A DiMeglio, Thue Johansen, Thomas Danne
Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Julia Brandts, Sascha R Tittel, Peter Bramlage, Thomas Danne, Johanna M Brix, Stefan Zimny, Christoph H J Heyer, Reinhard W Holl, Dirk Müller-Wieland
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry. Diabetes, obesity & metabolism (2023)
Evgeniya V Shalaeva, Arjola Bano, Ulugbek Kasimov, Bakhtiyor Janabaev, Thomas Danne, Hugo Saner
Impact of Persistent Medication Adherence and Compliance with Lifestyle Recommendations on Major Cardiovascular Events and One-Year Mortality in Patients with Type 2 Diabetes and Advanced Stages of Atherosclerosis: Results From a Prospective Cohort Study. Global heart 18 (1) (2023)
Stefanie Lanzinger, Frank Best, Tanja Bergmann, Markus Laimer, Boris Lipovsky, Thomas Danne, Stefan Zimny, Peter Bramlage, Svenja Meyhöfer, Reinhard W Holl
Dynamics of Hemoglobin A1c, Body Mass Index, and Rates of Severe Hypoglycemia in 4434 Adults with Type 1 or Type 2 Diabetes After Initiation of Continuous Glucose Monitoring. Diabetes technology & therapeutics 24 (10) (2022)
Thekla von dem Berge, Kerstin Remus, Sarah Biester, Felix Reschke, Britta Klusmeier, Kerstin Adolph, Anette Holtdirk, Andreas Thomas, Olga Kordonouri, Thomas Danne, Torben Biester
In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial. Diabetes, obesity & metabolism 24 (7) (2022)
Felix Reschke, Laura Galuschka, Sarah Landsberg, Chantal Weiner, Cathrin Guntermann, Evelin Sadeghian, Karin Lange, Thomas Danne
Successful telehealth transformation of a pediatric outpatient obesity teaching program due to the COVID-19 pandemic - the "Video KiCK" program. Journal of pediatric endocrinology & metabolism : JPEM 35 (6) (2022)
Tadej Battelino, Thomas Danne, Steve V Edelman, Pratik Choudhary, Pr Eric Renard, Jukka Westerbacka, Bhaswati Mukherjee, Valerie Pilorget, Mathieu Coudert, Richard M Bergenstal
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial. Diabetes, obesity & metabolism (2022)
Leszek Czupryniak, Thomas Danne, Elektra Szymańska-Garbacz, Dorota A Zozulinska-Ziolkiewicz, Janusz Gumprecht, Tomasz Klupa
Sodium-glucose co-transporter-2 inhibitors for type 1 diabetes: Not any more? Diabetes, obesity & metabolism 24 (4) (2022)
Moshe Phillip, Revital Nimri, Richard M Bergenstal, Katharine D Barnard-Kelly, Thomas Danne, Roman Hovorka, Boris P Kovatchev, Laurel H Messer, Christopher G Parkin, Louise Ambler-Osborn, Stephanie A Amiel, Lia Bally, Roy W Beck, Sarah Biester, Torben Biester, Julia E Blanchette, Emanuele Bosi, Charlotte K Boughton, Marc D Breton, Sue A Brown, Bruce A Buckingham, Albert Cai, Anders L Carlson, Jessica R Castle, Pratik Choudhary, Kelly L Close, Claudio Cobelli, Amy B Criego, Elizabeth A Davis, Carine de Beaufort, Martin I de Bock, Daniel J DeSalvo, J Hans DeVries, Klemen Dovc, Francis J Doyle, Laya Ekhlaspour, Naama Fisch Shvalb, Gregory P Forlenza, Geraldine Gallen, Satish K Garg, Dana C Gershenoff, Linda A Gonder-Frederick, Ahmad Haidar, Sara Hartnell, Lutz Heinemann, Simon Heller, Irl B Hirsch, Korey K Hood, Diana Isaacs, David C Klonoff, Olga Kordonouri, Aaron Kowalski, Lori M B Laffel, Julia Lawton, Rayhan A Lal, Lalantha Leelarathna, David M Maahs, Helen R Murphy, Kirsten Nørgaard, David O'Neal, Sean M Oser, Tamara K Oser, Pr Eric Renard, Michael C Riddell, David Rodbard, Steven J Russell, Desmond A Schatz, Viral N Shah, Jennifer L Sherr, Gregg D Simonson, R Paul Wadwa, Candice Ward, Stuart A Weinzimer, Emma G Wilmot, Tadej Battelino
Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice. Endocrine reviews (2022)
Stephan Kress, Peter Bramlage, Reinhard W Holl, Christian Dominik Möller, Steffen Mühldorfer, Jörg Reindel, Jochen Seufert, Rüdiger Landgraf, Ludwig Merker, Sebastian M Meyhöfer, Thomas Danne, Peter Fasching, Peter R Mertens, Christoph Wanner, Stefanie Lanzinger
Validation of a Risk Prediction Model for Early Chronic Kidney Disease in Patients with Type 2 Diabetes: Data from the German/Austrian DPV Registry. Diabetes, obesity & metabolism (2022)
Torben Biester, Thomas Danne
The Role of Sodium-Glucose Cotransporter Inhibitors with AID Systems in Diabetes Treatment: Is Continuous Ketone Monitoring the Solution? Diabetes technology & therapeutics 24 (12) (2022)
Thomas Danne, Stefanie Lanzinger, Martin de Bock, Erinn T Rhodes, Guy Todd Alonso, Pascal Barat, Yasmine Elhenawy, Melanie Kershaw, Banshi Saboo, Mauro Scharf Pinto, Agata Chobot, Klemen Dovc
A Worldwide Perspective on COVID-19 and Diabetes Management in 22,820 Children from the SWEET Project: Diabetic Ketoacidosis Rates Increase and Glycemic Control Is Maintained. Diabetes technology & therapeutics 23 (9) (2021)
Tadej Battelino, Ramin Tehranchi, Timothy S Bailey, Klemen Dovc, Anita Melgaard, Jenine Yager Stone, Stephanie Woerner, Thekla von dem Berge, Linda A DiMeglio, Thomas Danne
Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatric diabetes 22 (5) (2021)
Francesca Dassie, Francesca Favaretto, Silvia Bettini, Matteo Parolin, Marina Valenti, Felix Reschke, Thomas Danne, Roberto Vettor, Gabriella Milan, Pietro Maffei
Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity. Endocrine 71 (3) (2021)
Jochen Seufert, Stefanie Lanzinger, Thomas Danne, Peter Bramlage, Sebastian M Schmid, Florian Kopp, Stephan Kress, Peter Fasching, Claus Schäfer, Reinhard W Holl, null null
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis. Diabetes, obesity & metabolism 24 (4) (2021)
Torben Biester, Martin Tauschmann, Agata Chobot, Olga Kordonouri, Thomas Danne, Thomas Michael Kapellen, Klemen Dovc
The automated pancreas: A review of technologies and clinical practice. Diabetes, obesity & metabolism (2021)
Korey K Hood, Lori M B Laffel, Thomas Danne, Revital Nimri, Stuart A Weinzimer, Judy Sibayan, Ryan J Bailey, Desmond Schatz, Natasa Bratina, Rachel Bello, Alina Punel, Peter Calhoun, Roy W Beck, Richard M Bergenstal, Moshe Phillip
Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. Diabetes technology & therapeutics 23 (12) (2021)
Felix Reschke, Julia Rohayem, Pietro Maffei, Francesca Dassie, Anke Schwandt, Carine de Beaufort, Sonia Toni, Agnieszka Szypowska, Roque Cardona-Hernandez, Nicolin Datz, Katharina Klee, Thomas Danne
Collaboration for rare diabetes: understanding new treatment options for Wolfram syndrome. Endocrine 71 (3) (2021)
Thomas Danne, Munehide Matsuhisa, Christian Sussebach, Harmonie Goyeau, Felipe Lauand, Elisabeth Niemoeller, Geremia B Bolli
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials. Diabetes, obesity & metabolism 22 (10) (2020)
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2. Diabetes, obesity & metabolism 23 (3) (2020)
Olga Kordonouri, Torben Biester, Jürgen Weidemann, Hagen Ott, Kerstin Remus, Julia Grothaus, Nicole Pisarek, Reinhard Hartmann, Kerstin Adolph, Karin Lange, Thomas Danne
Lipoatrophy in children, adolescents and adults with insulin pump treatment: Is there a beneficial effect of insulin glulisine? Pediatric diabetes 21 (7) (2020)
Torben Biester, Thekla von dem Berge, Line Quist Bendtsen, Mette Dahl Bendtsen, Naveen Rathor, Thomas Danne, Hanne Haahr
The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes. Pediatric diabetes 21 (5) (2020)
Torben Biester, Ido Muller, Thekla von dem Berge, Eran Atlas, Revital Nimri, Moshe Phillip, Tadej Battelino, Natasa Bratina, Klemen Dovc, Markus F Scheerer, Olga Kordonouri, Thomas Danne
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. Diabetes, obesity & metabolism 23 (2) (2020)
Thomas Danne, Moshe Phillip, Bruce A Buckingham, Przemyslawa Jarosz-Chobot, Banshi Saboo, Tatsuhiko Urakami, Tadej Battelino, Ragnar Hanas, Ethel Codner
ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatric diabetes (2019)
Nandu Thalange, Larry Deeb, Georgeanna Klingensmith, Denise R Franco, Lars Bardtrum, Deniz Tutkunkardas, Thomas Danne
The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Pediatric diabetes 20 (3) (2019)
Thomas Danne, Anke Schwandt, Torben Biester, Bettina Heidtmann, Birgit Rami-Merhar, Holger Haberland, Silvia Müther, Semik Khodaverdi, Thomas Haak, Reinhard W Holl, null null
Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV registry. Pediatric diabetes 19 (5) (2018)
Danièle Pacaud, J M Hermann, B Karges, J Rosenbauer, Thomas Danne, R Dürr, A Herbst, S Lindauer, S Müther, S Pötzsch, K Raile, M Witsch, R W Holl, null null
Risk of recurrent severe hypoglycemia remains associated with a past history of severe hypoglycemia up to 4 years: Results from a large prospective contemporary pediatric cohort of the DPV initiative. Pediatric diabetes 19 (3) (2017)
Nicky Helen Kime, Sheridan Waldron, Elizabeth Webster, Karin Lange, Katarzyna Zinken, Thomas Danne, Bärbel Aschemeier, Zdenek Sumnik, Ondrej Cinek, João Filipe Raposo, Andriani Vazeou, Natasa Bratina, Fiona Campbell
Pediatric diabetes training for healthcare professionals in Europe: Time for change. Pediatric diabetes 19 (3) (2017)
Maryam Fath, Thomas Danne, Torben Biester, Lars Erichsen, Olga Kordonouri, Hanne Haahr
Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatric diabetes 18 (8) (2017)